Epstein Secrets

e Genetics $200,000 Cold-resistant elephants $2,500,000 2nd tranche $10,000,000 Total 1) Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) Using CRISPR to e

isms. We just published papers and patents on this. Lead by Dan Mandell. EFTA00631419 5) Eliminating ecosystem pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing

d-resistant elephants $2,500,000 2nd tranchc $10,000,000 Total 1) Supercentenarianstudv.com Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) eGenesisBio.com: U

resistant organisms. We just published papers and patents on this. Lead by Dan Mandell. 5) Eliminating ecosystem pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing

netics Cold-resistant elephants 2nd tranche $10,000,000 Total I ) Supercentenarianstudv.com Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) eGenesisBio.com: U

resistant organisms. We just published papers and patents on this. Lead by Dan Mandell. 5) Eliminating ecosystem pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing

logy Space Genetics Cold-resistant elephants 2nd tranche Total 1) Supercentenarianstudv.com Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) eGenesisBio.com: U

resistant organisms. We just published papers and patents on this. Lead by Dan Mandell. 5) Eliminating ecosystem pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing